FDA grants Amgen's Blincyto accelerated approval for MRD-positive ALL

FDA granted accelerated approval to Blincyto blinatumomab to treat B cell precursor acute lymphoblastic leukemia in patients who are in remission but still have minimal residual disease (MRD). The bispecific T cell engager (BiTE) against CD19 is the first drug FDA has approved to treat the condition...